The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

BACKGROUND AND OBJECTIVE: Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To evaluate the effect of hepatic impairment on the pharmacokinetics of...

Descripción completa

Detalles Bibliográficos
Autores principales: Piscitelli, Joseph, Chen, Joseph, LaBadie, Robert R., Salageanu, Joanne, Chung, Chin-Hee, Tan, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930943/
https://www.ncbi.nlm.nih.gov/pubmed/35195881
http://dx.doi.org/10.1007/s40261-022-01125-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930943/
https://www.ncbi.nlm.nih.gov/pubmed/35195881
http://dx.doi.org/10.1007/s40261-022-01125-x

Ejemplares similares